Skip to content
10-Q

Quarterly Report

SCPHARMACEUTICALS INC.

0000950170-25-071438

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 13, 2025 52.79M sh
Shares Diluted Q1 2025 · Mar 31, 2025 53.68M sh
Shares Diluted Q1 2025 · Mar 31, 2024 38.95M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$17.14M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$17.7M
Long Term Debt Q1 2025 · Mar 31, 2025 $51.05M
Long Term Debt Q1 2025 · Dec 31, 2024 $51.35M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $57.54M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $75.66M
Stockholders Equity Q1 2025 · Mar 31, 2025 −$5.13M
Stockholders Equity Q1 2025 · Dec 31, 2024 $13.32M
Stockholders Equity Q1 2025 · Mar 31, 2024 $24.57M
Stockholders Equity Q1 2025 · Dec 31, 2023 $37.22M
Current Liabilities Q1 2025 · Mar 31, 2025 $16.31M
Current Liabilities Q1 2025 · Dec 31, 2024 $14.88M
Total Liabilities Q1 2025 · Mar 31, 2025 $96.09M
Total Liabilities Q1 2025 · Dec 31, 2024 $94.2M
Current Assets Q1 2025 · Mar 31, 2025 $89.35M
Current Assets Q1 2025 · Dec 31, 2024 $105.85M
Total Assets Q1 2025 · Mar 31, 2025 $90.96M
Total Assets Q1 2025 · Dec 31, 2024 $107.52M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.37
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.36
Eps Basic Q1 2025 · Mar 31, 2025 −$0.37
Eps Basic Q1 2025 · Mar 31, 2024 −$0.36
Sga Expense Q1 2025 · Mar 31, 2025 $21.41M
Sga Expense Q1 2025 · Mar 31, 2024 $17.45M
Rd Expense Q1 2025 · Mar 31, 2025 $4.63M
Rd Expense Q1 2025 · Mar 31, 2024 $2.73M
Net Income Q1 2025 · Mar 31, 2025 −$19.74M
Net Income Q1 2025 · Mar 31, 2024 −$14.11M
Operating Income Q1 2025 · Mar 31, 2025 −$17.76M
Operating Income Q1 2025 · Mar 31, 2024 −$15.86M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $3.47M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $1.79M
Revenue Q1 2025 · Mar 31, 2025 $11.75M
Revenue Q1 2025 · Mar 31, 2024 $6.1M